The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...

HES can provide the kind of real-world evidence that some life sciences companies have a great deal of difficulty in ...

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

The merger of two pioneers of psychedelic medicines has completed with the creation of AtaiBeckley, a company with a pipeline ...

But once a cancer has been detected, the ability to quickly specify exactly which treatment will work is set to have a ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

"The UK's inability to retain economic benefits of its R&D is a fatal flaw to any growth strategy," according to the document ...